News and Announcements
MedAdvisor Achieves Another Record Quarter and Full Year Revenue Growth of +195%
- Published August 09, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Australia’s leading digital medication management company, MedAdvisor, achieved another quarter of revenue growth in the June 2017 quarter and reported FY17 revenue of $4.24 million, 197% higher than FY16 revenue of $1.43 million.
- This year MedAdvisor has grown its user base by a staggering +360%, with a total of 840,000 users now using the platform vs 180,000 in at the end of FY16.
- The pharmacy network now consists of over 2,600 pharmacies, representing nearly 50% of the nation’s pharmacies.
- Tap to Refill continued to grow with the total number of scripts ordered through the platform now totalling over $4 million per week, a ~300% increase on FY16 averages.
- During the year, Patient Engagement Programs (PEPs) saw significant growth of 200% with a total of 21 programs now live on the platform with leading manufacturers including GSK, Novartis, Bristol Myers Squibb, AstraZeneca and Pfizer.
- During the 2017 financial year, MedAdvisor raised $8 million to acquire Healthnotes and OzDocsOnline and to continue its expansion strategy.
- MedAdvisor recently appointed Dr David Chatterton as CTO who was previously CTO of Aconex (ASX:ACX) to help assist the business prepare for growth in new markets.
MedAdvisor closed the June 2017 quarter with $4.83 million cash and is targeting an expected cash flow breakeven in 2H CY2018.
ABOUT MEDADVISOR
MedAdvisor was established with a clear objective – develop and deliver the world’s most effective software for personal medication management, to help people make the best possible use of medication.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
